Many Patients Don't Receive Indicated Targeted NSCLC Therapy

The rates of use of targeted therapy among patients with EGFR- and ALK-mutations also varied across the US, dropping below 20% in some states.

Related Keywords

Boston , Massachusetts , United States , Arkansas , Georgia , Thomasj Roberts , , Network Open On , Drug Administration , Department Of Medicine , Massachusetts General Hospital , Medicaid Drug Utilization Database , Lung Cancer , Ung Carcinoma , Ancer Lung , Biologic Therapy , Targeted Therapy , Medicaid , Small Cell Lung Cancer , Anaplastic Lymphoma Kinase Alk , Lk Tyrosine Kinase Receptor , D246 Cluster Of Differentiation 246 , Cancer , Alignant Neoplasia , Arcinoma , Clinical Guidelines , Guidelines , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Hospitals , Lung , Ma ,